Robust TAVR Growth to Drive Edwards Lifesciences' Q3 Earnings

Core Insights - Edwards Lifesciences Corp. (EW) is set to report its third-quarter 2025 results on October 30, after market close [1][9] - The company’s adjusted earnings per share for the last quarter were 67 cents, exceeding the Zacks Consensus Estimate by 8.06%, with an average surprise of 5.50% over the past four quarters [1] Q3 Estimates - The Zacks Consensus Estimate for revenues is $1.50 billion, indicating an 11.5% growth from the previous year [2] - The earnings estimate is 59 cents per share, reflecting an 11.9% decline from the year-ago figure [2][3] Performance Factors - The Transcatheter Aortic Valve Replacement (TAVR) segment is expected to perform strongly in the U.S., driven by the SAPIEN 3 Ultra RESILIA platform, with projected sales of $1.11 billion, an 8.5% year-over-year increase [4][5][9] - The Transcatheter Mitral and Tricuspid Therapies (TMTT) segment is anticipated to report revenues of $134.1 million, a 47.2% increase from the previous year, supported by the PASCAL repair system and the EVOQUE tricuspid replacement system [6][7][9] - The Surgical Structural Heart segment is estimated to generate revenues of $256.7 million, reflecting a 7% rise from the year-ago quarter, aided by the global adoption of the RESILIA portfolio [10] Earnings Expectations - Edwards has an Earnings ESP of +0.47%, indicating a higher likelihood of beating estimates [11] - The company currently holds a Zacks Rank of 3, suggesting a neutral outlook [12]